Switch theme
Sign up to access all valuation multiples
Tasly Pharmaceutical Group Co Ltd is a China-based company engaged in the manufacturing and distribution of pharmaceutical products. Its herbal medicines include Tasly Cerebral Care Granules and Tasly ICP. Its chemical medicines comprise of Ketotifen Fumarate Tablets, Thiamphenicol Capsules, Glucurolactone Tablets and Sulpiride Tablets. Some of the other products offered by the company include PharmceuticalSubstances & API, HerbalExtract, and Concentrated Herbal Granules.
1998
3.4K+
LTM Revenue $1.2B
LTM EBITDA $246M
$3.2B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Tasly has a last 12-month revenue (LTM) of $1.2B and a last 12-month EBITDA of $246M.
In the most recent fiscal year, Tasly achieved revenue of $1.2B and an EBITDA of $226M.
Tasly expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Tasly valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $1.2B | XXX | $1.2B | XXX | XXX | XXX |
| Gross Profit | $807M | XXX | $792M | XXX | XXX | XXX |
| Gross Margin | 67% | XXX | 67% | XXX | XXX | XXX |
| EBITDA | $246M | XXX | $226M | XXX | XXX | XXX |
| EBITDA Margin | 21% | XXX | 19% | XXX | XXX | XXX |
| EBIT | $169M | XXX | $207M | XXX | XXX | XXX |
| EBIT Margin | 14% | XXX | 18% | XXX | XXX | XXX |
| Net Profit | $143M | XXX | $133M | XXX | XXX | XXX |
| Net Margin | 12% | XXX | 11% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Tasly's stock price is CNY 16 (or $2).
Tasly has current market cap of CNY 24.4B (or $3.4B), and EV of CNY 22.7B (or $3.2B).
See Tasly trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $3.2B | $3.4B | XXX | XXX | XXX | XXX | $0.10 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Tasly has market cap of $3.4B and EV of $3.2B.
Tasly's trades at 2.7x EV/Revenue multiple, and 14.0x EV/EBITDA.
Equity research analysts estimate Tasly's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Tasly has a P/E ratio of 23.7x.
See valuation multiples for Tasly and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $3.4B | XXX | $3.4B | XXX | XXX | XXX |
| EV (current) | $3.2B | XXX | $3.2B | XXX | XXX | XXX |
| EV/Revenue | 2.6x | XXX | 2.7x | XXX | XXX | XXX |
| EV/EBITDA | 12.8x | XXX | 14.0x | XXX | XXX | XXX |
| EV/EBIT | 18.6x | XXX | 15.2x | XXX | XXX | XXX |
| EV/Gross Profit | 3.9x | XXX | n/a | XXX | XXX | XXX |
| P/E | 23.7x | XXX | 25.5x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 15.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialTasly's last 12 month revenue growth is 5%
Tasly's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.2M for the same period.
Tasly's rule of 40 is 26% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Tasly's rule of X is 34% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Tasly and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 5% | XXX | 5% | XXX | XXX | XXX |
| EBITDA Margin | 21% | XXX | 19% | XXX | XXX | XXX |
| EBITDA Growth | 8% | XXX | 1% | XXX | XXX | XXX |
| Rule of 40 | 26% | XXX | 24% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 34% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 25% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 10% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 50% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Tasly acquired XXX companies to date.
Last acquisition by Tasly was XXXXXXXX, XXXXX XXXXX XXXXXX . Tasly acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Tasly founded? | Tasly was founded in 1998. |
| Where is Tasly headquartered? | Tasly is headquartered in China. |
| How many employees does Tasly have? | As of today, Tasly has 3.4K+ employees. |
| Is Tasly publicy listed? | Yes, Tasly is a public company listed on SHG. |
| What is the stock symbol of Tasly? | Tasly trades under 600535 ticker. |
| When did Tasly go public? | Tasly went public in 2002. |
| Who are competitors of Tasly? | Similar companies to Tasly include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Tasly? | Tasly's current market cap is $3.4B |
| What is the current revenue of Tasly? | Tasly's last 12 months revenue is $1.2B. |
| What is the current revenue growth of Tasly? | Tasly revenue growth (NTM/LTM) is 5%. |
| What is the current EV/Revenue multiple of Tasly? | Current revenue multiple of Tasly is 2.6x. |
| Is Tasly profitable? | Yes, Tasly is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Tasly? | Tasly's last 12 months EBITDA is $246M. |
| What is Tasly's EBITDA margin? | Tasly's last 12 months EBITDA margin is 21%. |
| What is the current EV/EBITDA multiple of Tasly? | Current EBITDA multiple of Tasly is 12.8x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
